Patent intelligence · US
US 11845726
C4-carbonothioate-substituted tryptamine derivatives and methods of using
C4-carbonothioate-substituted tryptamine derivatives and methods of using
Patent details — US 11845726
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 19, 2023
- Expiration
- Dec 14, 2043
- Applicant
- Enveric Biosciences Canada Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/4045, A61P, A61P25/00
Quick answer
US 11845726 (C4-carbonothioate-substituted tryptamine derivatives and methods of using) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enveric Biosciences Canada Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/4045, A61P, A61P25/00
More from Enveric Biosciences Canada Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428408
Fused heterocyclic mescaline derivatives
granted -
US 12378195
Aminated psilocybin derivatives and methods of using
granted -
US 12358885
Substituted n-propylamine fused heterocyclic mescaline derivatives
granted -
US 12338231
N-heterocycle substituted tryptamine derivatives and methods of using
granted -
US 12195439
C1-substituted isopropylamine fused heterocyclic mescaline derivatives
granted -
US 12187679
Hydroxylated psilocybin derivatives and methods of using
granted -
US 12138276
Halogenated psilocybin derivatives and methods of using
granted -
US 12133856
Multi-substituent psilocybin derivatives and methods of using
granted
Frequently asked questions
What is US patent 11845726?
US 11845726 (C4-carbonothioate-substituted tryptamine derivatives and methods of using) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11845726?
Enveric Biosciences Canada Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 11845726 expire?
Our index shows an expiration date of Dec 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.